Funding
Wonder Raised $650 Million to Make Dinner a Robot-Mediated IPO Problem
Wonder raised $650 million at a $9 billion valuation to scale robot kitchens, food halls, AI, and delivery. The ambition is real. So is the burn.
Funding
Wonder raised $650 million at a $9 billion valuation to scale robot kitchens, food halls, AI, and delivery. The ambition is real. So is the burn.
Funding
Mio wants to turn Slack into a place where follow-ups actually happen. A slightly unnerving AI coworker pitch with a surprisingly practical wedge.
Startups
Guthrie AI raised $4 million to help glazing contractors bid faster with virtual assistants and workflow automation. Extremely niche, oddly lovable, and more practical than most AI theater.
AI
Ollama's new round says local and open-weight AI is no longer a hobby. It is becoming enterprise plumbing, with fewer tokens and more GPU invoices.
Funding
Marker raised $13 million to build an AI writing tool for drafts, revisions, and half-formed thoughts. Earnest, stylish, and surprisingly sane about the craft.
Startups
Aardaia just raised €5 million to turn a forgotten tuber into Europe's homegrown protein crop. Strange pitch, serious science, and better timing than it has any right to have.
Startups
Norm Ai's $120 million Series C bets regulated enterprises want AI wrapped in lawyers, audit trails, and outcome pricing. Annoyingly, that sounds rational.
Startups
Even Realities raised $150 million for camera-free smart glasses. The privacy-first pitch is smart. The face-computer trust problem is still very real.
Startups
Reed Semiconductor's $100 million round says the AI boom is now financing power delivery. Annoying, essential, and far more strategic than it sounds.
Startups
Taktile raised $110 million to automate high-stakes banking and insurance decisions. The pitch is serious, the controls matter, and the weirdness tax is real.
Startups
Cadence raised $100 million to turn chronic care into clinician-supervised AI logistics. The need is real, the economics are compelling, and the Medicare math is finally getting weird.
Boston Tech
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.